Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

NHS funding

Gething confirms £80m fund for high-cost medicines in Wales

Vaughan Getting, speaking at the RPS conference

Source: Royal Pharmaceutical Society

Vaughan Gething also confirmed there would be a review of the individual patient funding request process for medicines that are not yet approved for use

A central fund worth £80m that will pay for the immediate use of new, high-cost medicines that are approved for use in Wales has been announced by Vaughan Gething, cabinet secretary for health for the Welsh government.

The Welsh government fund will become available in 2016 to pay for high-cost medicines for the 12 months after they are approved by the National Institute for Health and Care Excellence or the All-Wales Medicines Strategy Group. After that, funding for such medicines is expected to be provided by regional health boards.

“It is essential the fund is operated transparently and is widely understood,” says Gething. “During the summer we will be working hard to define the criteria and mechanisms that will be needed to manage the fund effectively.” The fund was pledged by Welsh Labour in its manifesto for the Welsh Assembly elections, which took place earlier in 2016.

Gething also confirmed there would be a review of the individual patient funding request process for medicines that are not yet approved for use. He explained the review was intended to “ensure better consistency of decisions across Wales and make recommendations about what clinical criteria should be applied when determining [patient eligibility for funding]”.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201460

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 1 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Vaughan Getting, speaking at the RPS conference

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.